Suprofen
![]() | |
Clinical data | |
---|---|
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Routes of administration | Oral, eye drops |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 20% |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.050.071 |
Chemical and physical data | |
Formula | C14H12O3S |
Molar mass | 260.31 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Suprofen is a nonsteroidal anti-inflammatory drug (NSAID) developed by Janssen Pharmaceutica[1] that was marketed as 1% eye drops under the trade name Profenal.
Uses
[edit]Suprofen was originally used as tablet, but oral uses have been discontinued due to renal effects.[2] It was subsequently used exclusively as a topical ophthalmic solution, typically to prevent miosis during and after ophthalmic surgery.[3] This application has been discontinued as well, at least in the US.[4]
References
[edit]- ^ DE 2353357, Janssen PA, Van Daele GH, Boey JM, "Antiphlogistic aroyl-substituted phenylacetic acid derivatives", issued 1974
- ^ Nies AS (1988). "Renal Effects of Nonsteroidal Anti-Inflammatory Drugs". Basis for Variability of Response to Anti-Rheumatic Drugs. Vol. 24. pp. 95–106. doi:10.1007/978-3-0348-9160-8_9 (inactive 2024-02-09). ISBN 978-3-0348-9931-4. PMID 3142236.
{{cite book}}
:|journal=
ignored (help)CS1 maint: DOI inactive as of February 2024 (link) - ^ "Pharmacy Compounding". Guidance for FDA Staff and Industry Compliance Policy Guides Manual. U.S. Food and Drug Administration. Archived from the original on 1 January 2009.
- ^ "Suprofen ophthalmic". Drugs.com. Archived from the original on 2021-09-09. Retrieved 2018-01-23.